News articles about Obalon Therptcs (NASDAQ:OBLN) have trended somewhat positive on Saturday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Obalon Therptcs earned a news impact score of 0.05 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.6532510708921 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- $3.52 Million in Sales Expected for Obalon Therptcs (OBLN) This Quarter (americanbankingnews.com)
- ETFs with exposure to Obalon Therapeutics, Inc. : November 21, 2017 (finance.yahoo.com)
- Obalon Therptcs (OBLN) versus The Competition Financial Review (americanbankingnews.com)
- Zacks: Analysts Anticipate Obalon Therptcs (OBLN) to Post -$0.48 EPS (americanbankingnews.com)
- Are You Backing The Right Horse With Obalon Therapeutics Inc (OBLN)? (finance.yahoo.com)
Shares of Obalon Therptcs (OBLN) opened at $8.05 on Friday. The company has a current ratio of 8.78, a quick ratio of 8.65 and a debt-to-equity ratio of 0.21. Obalon Therptcs has a 1-year low of $7.60 and a 1-year high of $13.18.
A number of research firms have recently issued reports on OBLN. Zacks Investment Research upgraded shares of Obalon Therptcs from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. BTIG Research cut their price target on shares of Obalon Therptcs from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, November 6th. UBS AG restated a “buy” rating and set a $20.00 price target (down previously from $22.00) on shares of Obalon Therptcs in a report on Wednesday, August 9th. Finally, Northland Securities restated a “sell” rating and set a $6.00 price target on shares of Obalon Therptcs in a report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $13.00.
ILLEGAL ACTIVITY NOTICE: “Obalon Therptcs (OBLN) Earning Somewhat Favorable News Coverage, Report Shows” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.com-unik.info/2017/11/25/obalon-therptcs-obln-earning-somewhat-favorable-news-coverage-report-shows.html.
About Obalon Therptcs
Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
What are top analysts saying about Obalon Therptcs? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Obalon Therptcs and related companies.